Amgen Inc Stock Price, News & Analysis

Amgen (NASDAQ:AMGN) will host a webcast call on January 29, 2021, at 8:00 p.m. ET, in conjunction with the 2020 World Conference on Lung Cancer. The call will feature Dr. David M. Reese and Amgen's clinical team discussing Phase 2 data on their investigational KRAS^G12C inhibitor, sotorasib, for treating non-small cell lung cancer (NSCLC). The live audio will be accessible online to media, investors, and the public, with replays available for 90 days post-event.

For more details, visit www.amgen.com.

Amgen announced significant findings from its oncology pipeline at the 2020 World Conference on Lung Cancer, focusing on sotorasib, a KRAS G12C inhibitor for advanced non-small cell lung cancer (NSCLC). The Phase 2 data from the CodeBreaK 100 study will be presented during the Presidential Symposium on January 29, 2021. These results mark a milestone in targeting KRAS mutations, addressing an unmet need for 25,000 new patients diagnosed in the U.S. annually. Amgen aims to expedite the therapy's regulatory approval as it moves forward in clinical development.

Amgen (NASDAQ: AMGN) has launched a seven-year environmental sustainability plan, aiming for carbon neutrality by 2027. The company plans to reduce water use by 40% and waste disposal by 75%. Since 2007, Amgen achieved a 33% reduction in carbon emissions even while expanding production and revenue. The initiative involves an investment of over $200 million to enhance sustainability and operational efficiencies. Innovations include biomanufacturing plants that produce 70% less carbon compared to traditional facilities, aiming to engage suppliers in carbon reduction efforts as well.

Amgen (NASDAQ:AMGN) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 11:50 a.m. PT. CEO Robert A. Bradway will lead the presentation, which will be accessible live via Amgen's website. A replay will be available for 90 days post-event. As a leading biotechnology company, Amgen is focused on advancing therapies for serious illnesses by leveraging human genetics to address unmet medical needs. The company has a robust pipeline and aims to enhance health outcomes for patients globally.

Amgen has entered a licensing agreement with Medicines Development for Global Health (MDGH) for AMG 634, a PDE4 inhibitor aimed at treating tuberculosis and erythema nodosum leprosum. AMG 634 is currently in Phase 2 trials led by the Aurum Institute and The Leprosy Mission Nepal. Amgen acquired the compound during its purchase of Otezla from Celgene in 2019. MDGH will oversee further development and commercialization, with Amgen providing support for ongoing clinical trials. This collaboration aims to address unmet health needs in low- and middle-income countries.

Amgen (NASDAQ: AMGN) announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for sotorasib, a KRAS^G12C inhibitor aimed at treating adult patients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC). This submission reflects Amgen's commitment to expedite the clinical program for sotorasib, which has shown positive outcomes in Phase 2 trials. With approximately 33,000 new KRAS G12C NSCLC cases diagnosed annually in the EU-27, this therapy addresses a significant unmet medical need.

Amgen and AstraZeneca announced that the SOURCE trial did not achieve its primary endpoint of significantly reducing daily oral corticosteroid (OCS) doses in severe asthma patients treated with tezepelumab compared to placebo. The 48-week trial involved 150 patients and aimed to assess tezepelumab's efficacy and safety. Despite the SOURCE results, previous trials, including the NAVIGATOR study, showed promising outcomes with tezepelumab, which is designed to block thymic stromal lymphopoietin (TSLP) involved in asthma inflammation. Further analyses are ongoing, and safety profiles remain consistent with prior studies.

Amgen (NASDAQ: AMGN) and LabCentral announced the winners of the Amgen Golden Ticket for 2020, awarded to Octagon Therapeutics and Seranova Bio. Chosen during a virtual pitch event, these biotech start-ups will receive one year of free bench space and mentorship from Amgen scientists. Octagon is developing targeted immunomodulators for autoimmune diseases, while Seranova is focused on novel therapeutic target discovery using its advanced REAP platform. This initiative highlights Amgen's commitment to supporting innovative life sciences companies.

Amgen announced FDA approval for RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, for treating adult patients with Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Granulomatosis with Polyangiitis, and Microscopic Polyangiitis. RIABNI will launch in the U.S. in January 2021, priced 23.7% lower than Rituxan, at $716.80 per 100 mg and $3,584.00 per 500 mg. The approval reinforces Amgen's commitment to providing affordable biosimilars and follows the success of KANJINTI and MVASI. Clinical studies show RIABNI is clinically equivalent to Rituxan in safety and efficacy.